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The JNK and P38α pathways play an important role in the sensitivity and outcomes of chemotherapy.We hypothesize that
functional single nucleotide polymorphisms (SNPs) of genes of these pathways modulate outcomes of patients with
advanced non–small cell lung cancer (NSCLC) treated with first-line platinum-based chemotherapy (PBC). We selectively
genotyped 11 independent, potentially functional SNPs of 9 genes in the JNK and P38α pathways first in a discovery group
of 355 patients with advanced NSCLC treatedwith PBC, andwe evaluated their associationswith progression-free survival
(PFS) andoverall survival (OS) byCoxproportional hazards regression analysis. Then, resultant significant SNPswere further
validated in a replication group of 355 patients. In both discovery and validation groups as well as their combined analysis,
theMAPK14 rs3804451GA/AAgenotypesshowedastrongassociationwith a reducedPFS (adjustedhazards ratio [HR] = 1.39;
95%confidence interval [CI] = 1.16–1.66;P = .0003) andOS (adjustedHR = 1.41; 95%CI = 1.11-1.80;P = .005) compared
with thewild-typeGGgenotype. Incontrast, patientswithorwithout theMAPK14 rs3804451Aallelehadnosignificantdifference
inOS in response to tyrosine-kinase inhibitor treatment (adjustedHR = 0.86;95%CI = 0.56-1.33;P = .505). Thepresentstudy
provides evidence that theMAPK14 rs3804451GNAvariantmaymodulate survival outcomes in patientswith advancedNSCLC
treated with PBC. Larger studies of additional patient populations are needed to validate our findings.
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Non–small cell lung cancer (NSCLC), accounting for more than 80% of
all lung cancer cases, is one of the most fatal humanmalignancies [1,2]. In
particular, a large number of patients are diagnosed at an advanced stage
(i.e., stage III or IV) [3] because there were no obvious symptoms that
could draw medical attention at their early stages [4]. Platinum-based
(cisplatin or carboplatin) double-agent chemotherapies are widely used as
the standard first-line treatment for patients with advanced NSCLC
without sensitive EGFR mutations (NCCN guidelines, http://www.
nccn.org/professionals/), which have led to improved survival outcomes.
However, the efficacy of different combinations is not satisfying because
the response rate of most clinical trials has been no more than 40% [5].
The main action site of platinum compounds is thought to be
DNA, causing inter- and intrastrand cross-links that lead to damages
of DNA, activation of apoptosis signaling pathways, and death of
cancer cells [6]. Nonetheless, a significant fraction of lung cancer
patients bears neoplastic lesions that are intrinsically resistant to
genocytotoxic effects of platinum compounds [7]. This suggests that
intrinsic resistance to platinum-based chemotherapy (PBC) is an
important limiting factor in the treatment of NSCLC. As a matter of
fact, numerous clinical studies have elucidated that genetic factors
may be associated with the response and outcomes of PBC [8–10].
Thus, interindividual genetic variation may play an important role in
determining outcomes of NSCLC patients treated with PBC [11].
Stress-activated MAPKs, such as P38 MAPK and JNK, are well
known for their effects on controlling apoptosis and autophagic death
after genotoxic stresses [12], and thus, they seem to play an important
role in the sensitivity and outcomes of PBC [13]. Several studies have
shown that the posttarget cisplatin resistance was associated with
defects in several apoptotic signal transducers, including JNK and
P38 pathways [7]. In cisplatin-resistant NSCLC cell lines, for
example, functional inhibition of the JNK/ATF2 pathway could
restore the sensitivity to cisplatin [14], but the upregulating of P38α
MAPK might promote chemoresistance in lung adenocarcinoma cells
[15]. These results indicate that the activation of the JNK and P38α
pathways probably affect the outcomes of NSCLC patients treated
with PBC. Previous studies also reported that genetic variants in genes
involved in DNA repair and apoptosis were associated with survival of
NSCLC patients treated by PBC [11,16–18]. Currently, there is still
a lack of studies on associations between genetic variants in genes of
the JNK and P38α pathways and chemotherapy outcome. Therefore,
we performed a retrospective two-stage analysis in a cohort of patients
with advanced NSCLC treated with PBC to assess the effects of
genetic variants of genes in JNK and P38α pathways on the response
to PBC and survival outcomes in these patients.
Materials and Methods
Study Subjects and Follow-Up
In the present study, we recruited patients with histologically
confirmed advanced NSCLC from our institution. The discovery
group consisted of 355 NSCLC patients recruited between February
2009 and February 2012, whereas the replication group included 355
NSCLC patients recruited between March 2012 and November
2013. All participants were genetically unrelated ethnic Han Chinese,
and none had blood transfusions in the last 6 months. Recruitment
criteria were as follows: inoperable TNM stages III to IV tumors; no
prior history of cancer except for an in situ carcinoma; receiving PBC
as the first-line treatment; Eastern Cooperative Oncology Group(ECOG) performance status 0 to 2; required laboratory values for
blood tests and uronoscopy in normal range and no active infection or
serious medical (e.g., recent myocardial infarction, active congestive
heart failure, cardiac arrhythmia, or cerebral apoplexy, etc.) or
psychological (e.g., crankiness or depression etc.) factors that might
prevent patients from adherence to treatment schedule.
Demographic and other clinical data (i.e., age at treatment, sex,
smoking history, ECOG performance status, TNM stage, histologic
grade, histological type, chemotherapy regimens, radiotherapy,
tyrosine-kinase inhibitor [TKI] treatment and grade 3/4 overall
chemotherapy toxicity [including hematological toxicity and gastro-
intestinal toxicity]) were collected from patients' medical records. The
initial chemotherapy response was evaluated after the second cycle of
chemotherapy by computed tomography and magnetic resonance
imaging scans using the Response Evaluation Criteria in Solid Tumor
guidelines [19]. In the present study, progressive disease (PD)was defined
as drug resistance, whereas complete response (CR), partial response (PR),
and stable disease (SD) were identified as non–drug resistance.
Survival data were collected from patients' next of kin through a
telephone follow-up and inpatient and outpatient clinical medical
records. Overall survival (OS) time was calculated from the date when
patients first received chemotherapy until the date of the last follow-up or
death. Progression-free survival (PFS) time was calculated from the date
when patients first received chemotherapy until the date of progression or
the last follow-up or death. The median follow-up period was 32.1
months. The present study was approved by our Institutional Review
Board, and all participants provided a written informed consent.
Chemotherapy Regimens
All patients enrolled in the study were given the first-line
platinum-based chemotherapy, that is, cisplatin (75 mg/m2) or
carboplatin (area under the curve [AUC] 6 mg/ml·min), administered
on day 1 every 3 weeks, in combination with paclitaxel (175 mg/m2) on
day 1 every 3 weeks, docetaxel (75 mg/m2) on day 1 every 3 weeks,
gemcitabine (1250 mg/m2) on days 1 and 8 every 3 weeks, pemetrexed
(500mg/m2) on day 1 every 3 weeks or vinorelbine (25 mg/m2) on days
1 and 8 every 3 weeks, and cisplatin (100mg/m2) or carboplatin (AUC 6
mg/ml·min) administered on day 1 every 4 weeks, in combination with
etoposide (100 mg/m2) on days 1 to 3 every 4 weeks. All
chemotherapeutic drugs were administered intravenously.
Single Nucleotide Polymorphism (SNP) Selection and Genotyping
All blood samples were collected from the tissue bank of our
institution. Genomic DNA was extracted from blood samples of all
the study subjects by using the DNA Blood Mini Kit (Qiagen,
Valencia, CA). Preselected 11 independent, potentially functional
SNPs of 9 key genes (GADD45A, GADD45B, GADD45G,
MAP2K7, MAP2K4, MAP3K4, MAPK8, MAPK9, and MAPK14)
[20,21] involved in the JNK and P38α pathways were genotyped by
using the TaqMan allelic discrimination assay on the ABI7900 HT
sequence detector system (Applied Biosystems, Foster City, CA) [22].
More detailed information is provided in Supplemental Table S1. We
further randomly selected 10% samples for each of the selected SNPs
for regenotyping, and the results were 100% concordant.
Tissue Preparation, and RNA and DNA Extraction
Non–small cell lung cancer tumor tissues were dissected and
evaluated by two pathologists after surgical removal, and the leftover
tumors tissues were transferred into liquid nitrogen immediately after
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Pathology and Tissue Bank. For the present study, 170 tumor tissue
samples were randomly selected for mRNA expression analysis. Both
RNA and DNA were extracted from tumor tissue samples with the
TRIzol reagent (Invitrogen, Carlsbad, CA) and the DNA kit
(Tiangen, Beijing, China). RNA samples were used to synthesize
complementary DNA with the PrimeScript RT Master Mix system
(Takara, Otsu, Japan), as previously described [23]. The DNA
samples were used for genotyping as mentioned above.
Real-Time Polymerase Chain Reaction (PCR)
The samples of total RNA from the 170 target tissues were used for the
real-time reverse transcriptase PCR to detect mRNA expression, which
was performed using the ABI-Prism 7900 sequence detection system
(Applied Biosystems, Foster City, CA) as previously described [23,24].
The primers used for the real-time reverse transcriptase PCR were
5′-AACCTGTCTCCAGTGGGCTCT-3′ and 5′-CGTAACCC
CGTTTTTGTGTCA-3′ for MPAK14[25] and 5′-GAACGGGAAG
CTCACTGG-3′ and 5′-GCCTGCTTCACCACCTTCT-3′ for
GAPDH[26].
Statistical Analysis
To minimize false-positive report probability [27] and to show the
internal consistency, a two-stage analysis was performed to investigate
associations between the selected SNPs and PFS/OS. The association
between each genetic variant and PFS/OS was estimated by using the
Cox proportional hazards regression models with adjustment for
confounders and depicted by the Kaplan-Meier method. All 11 SNPs
were first evaluated in the discovery group, and those SNPs that had a
P value b.05 by either the trend or genotype tests for associations with
PFS/OS in Cox regression models were further validated in the
replication group. Finally, SNPs that met the same criteria in the
replication group were further subjected to the combined analyses for
all subjects. The observed associations were also evaluated in
subgroup analyses, stratified by selected demographic and clinical
variables. The heterogeneity between subgroups was assessed with the
χ2-based Q test. Multiplicative interactions were assessed by Cox
regression models. Associations between SNPs and chemotherapy
response were also estimated by comparing individuals with drug
resistance to those without in unconditional logistic regression
models. Predictive values of both the selected variables only and their
combination with SNPs were evaluated by incident/dynamic (I/D)
AUC of the receiver-operator characteristic (ROC) curves for
censored data and concordance index (C index) for comparison of
survival models [28]. Variables in the predictive model were selected
using a backward-stepwise Cox regression process with a maximum
iteration of 20 and an entry possibility of .05 as well as an excluded
possibility of .10 at each step. The I/D ROC and I/D AUC were
calculated and plotted by using risksetROC package [29] of R
software (version 3.2.3;The R Foundation for Statistical Computing),
whereas 95% confidence intervals (CIs) of C index and AUCs of
time-dependent ROC curves were calculated by using the bootstrap
method with 1000 replications. Linear regression analysis and Student's t
tests were applied to the comparison of mRNA levels between samples by
genotypes. To control for the multiple testing, the conservative
Bonferroni correction was used. Unless otherwise specified, all tests
were two-sided by using the SAS software (version 9.3; SAS Institute,
Cary, NC) andGraphPad Prism 5 (GraphPad Software, Inc., San Diego,
CA). P b .05 was considered statistically significant.Results
Characteristics of the Study Population
The distributions of demographic variables and clinical
information are described in Supplemental Table S2. Overall, 710
patients were included in the analysis, amongwhich 508weremales and
202 were females. The median age was 58 (23-83) years, 334 (47.0%)
were nonsmokers, 41 (5.8%) were former smokers, and 335 (47.2%)
were current smokers. The chemotherapy regimen consisted of
docetaxel/paclitaxel, etoposide, gemcitabine, vinorelbine, pemetrexed,
and cisplatin or carboplatin. A total of 30.8% of patients received
palliative radiotherapy, and 36.2% received TKI treatment.
PFS and OS by Clinical Characteristics of Patients with NSCLC
Supplemental Table S3 and Supplemental Figure S1 show the
associations between clinical characteristics and patients' survival. The
TKI treatment was used only after the patients presented disease
progression; therefore, it was excluded from the confounding factors
of PFS. In the univariate Cox regression model, sex (Supplemental
Figure S1, C and D), smoking status (Supplemental Figure S1, G and
H), TNM stages (Supplemental Figure S1, I and J) and palliative
radiotherapy (Supplemental Figure S1, U and V) were significant for
PFS and OS. The ECOG performance status (0-1 vs 2; HR = 1.19;
95% CI = 1.01-1.40; P = .035) (Supplemental Figure S1 E) showed
a significant association with PFS, and it also showed a similar
tendency toward significance for OS (0-1 vs 2; HR = 1.19; 95%
CI = 0.95-1.48; P = .126) (Supplemental Figure S1 F). Other
possible confounding factors such as different chemotherapy
regimens (docetaxel/paclitaxel, etoposide, gemcitabine, vinorelbine,
and pemetrexed) (Supplemental Figure S1 O) did not show
significance associations with PFS (log-rank P = .575), but patients
treated with gemcitabine seemed to have a shorter OS (HR = 1.46;
95% CI = 1.08-1.96; P = .014) when compared with those treated
with docetaxel/paclitaxel (Supplemental Figure S1 P). In addition,
TKI treatment was associated with significantly increased OS of
patients (25.5 vs 33.7 months; HR = 0.77; 95% CI = 0.62-0.97;
P = .024) (Supplemental Figure S1 W). However, to control for
any possible confounding on the main effects of the studied SNPs on
OS, age at treatment, sex, TNM stage, smoking status, histological
type, histologic grade, ECOG performance status, chemotherapy
regimens, grade 3/4 chemotherapy toxicity, palliative radiotherapy,
and TKI treatment were all further adjusted in the subsequent
multivariate Cox regression analysis.
Selected SNPs and NSCLC Survival
The distributions of genotypes of all the investigated 11 SNPs in
the discovery group were in accordance with Hardy-Weinberg
equilibrium (P N .05), and the observed minor allele frequency of
each SNP was consistent with that previously reported in HapMap
database. In the discovery group, among the SNPs evaluated, four
SNPs (GADD45A rs581000, MAP2K7 rs3679, and MAPK14
rs3804451) and four SNPs (GADD45A rs581000, MAP3K4
rs1488, MAP3K4 rs678290 and MAPK14 rs3804451) were
associated with PFS and OS, respectively (P b .05 by the trend test
or genotype test in Cox proportional hazards regression models)
(Supplemental Tables S4 and 5); however, onlyMAPK14 rs3804451
was found to be associated with a shorter PFS and OS by using the
criteria previously described in the replication group and subjected to
the combined analysis (Table 1).




PHWE Event/No. MST (mo) P
† Adjusted HR‡ (95% CI) P‡ Event/No. MST (mo) P† Adjusted HR§ (95% CI) P§
Discovery group .594 .014 ¶ .0003¶,#
GG 212/254 7.2 .067 1.00 (ref.) 119/254 35.2 .053 1.00 (ref.)
GA 85/91 6.2 1.26 (0.97-1.65) .080 53/91 25.3 1.71 (1.19-2.43) .003#
AA 8/10 4.1 2.29 (1.10-4.76) .027 5/10 10.8 3.72 (1.41-9.78) .008
GA/AA 93/101 6.1 .032 1.32 (1.02-1.70) .034 58/101 25.3 .023 1.79 (1.27-2.53) .001#
Replication group .422 .001¶,# .049 ¶
GG 210/258 7 .022 1.00 (ref.) 111/258 26.8 .434 1.00 (ref.)
GA 79/87 7.7 1.45 (1.10-1.91) .008 38/87 23.5 1.28 (0.86-1.9) .232
AA 10/10 3.8 2.30 (1.16-4.55) .017 6/10 24.9 2.55 (0.99-6.6) .053
GA/AA 89/97 6.6 .008 1.51 (1.16-1.97) .002# 44/97 23.5 .483 1.37 (0.94-2.00) .104
All combined .346 b.0001¶,# .001¶,#
GG 422/512 7.2 .002 1.00 (ref.) 230/512 32.1 .034 1.00 (ref.)
GA 164/178 6.6 1.34 (1.12-1.62) .002# 91/178 24.4 1.34 (1.04-1.72) .024
AA 18/20 3.4 2.07 (1.27-3.35) .003# 11/20 19.8 2.67 (1.42-5.00) .002#
GA/AA 182/198 6.5 .001 1.39 (1.16-1.66) .0003# 102/198 24.4 .033 1.41 (1.11-1.80) .005
The results were in bold if P b .05.
P
HWE
: P value for Hardy-Weinberg equilibrium test.
† P: value for log-rank tests.
‡ Data were calculated using Cox regression, adjusted by age at treatment, sex, smoking status, TNM stage, histological type, histologic grade, ECOG performance status, chemotherapy regimens, grade 3/4 chemotherapy
toxicity, and palliative radiotherapy.
§ Data were calculated using Cox regression, adjusted by age at treatment, sex, smoking status, TNM stage, histological type, histologic grade, ECOG performance status, chemotherapy regimens, grade 3/4 chemotherapy
toxicity, palliative radiotherapy, and TKI treatment.
¶ Ptrend: P value for trend.
# Significance remained after Bonferroni correction.
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allele was found to be significantly associated with poor PFS and OS in
NSCLC patients. Patients with rs3804451GA/AA genotypes showed a
reduced PFS compared with the wild-type GG homozygotes (6.5 vs 7.2
months; log-rank P = .001; HR = 1.39; 95% CI = 1.16-1.66; adjusted
P = .0003) (Figure 1B). The median survival time (MST) for patients
with rs3804451GA/AA genotypes (MST =24.4 months) was shorter
than that for those with the GG genotype (32.1 months; log-rank P =
.033; HR = 1.41; 95% CI = 1.11-1.80; adjusted P = .005) (Figure
1D), and the significance remained after Bonferroni correction (Table 1).
We compared I/D AUC of the time-dependent ROC curves and
estimatedC index to assess the discriminative accuracy of the OS prediction
model by removing the rs3804451 SNP from the model as selected by a
backward-stepwise Cox regression process. The rank of the I/D AUC
prediction model including all selected variables (i.e., rs3804451, sex,
smoking status, TNM stage, palliative radiotherapy, and TKI treatment)
was higher than the model that only included clinical variables at 1
(Figure 2A), 3 (Figure 2B), and 5 (Figure 2C) years forOS (Supplemental
Table S6), whereas the C index also decreased from 0.621 (95% CI =
0.586-0.646) to 0.612 (95% CI = 0.580-0.635) (Figure 2D), although the
differencewas not statistically significant (P = .321) (Supplemental Table S6).
The rs3804451 SNP and Chemotherapy Response
The association between the MAPK14 rs3804451 SNP and
chemotherapy responses is summarized in Supplemental Table S7.
Compared with the rs3804451GG genotype, variant GA/AA genotypes
were associated with a higher risk of PBC resistance (GA/AA versus GG;
adjusted OR =1.91; 95% CI = 1.24-2.93; P = .003), assuming a
dominant effect of the A allele (Supplemental Table S7).
Stratified Analysis of the Associations of MAPK14 rs3804451
with PFS and OS
In stratification analyses, by assuming a dominant genetic model, the
effect of the rs3804451A allele was still statistically significant in most of
the subgroups, except for those subgroups with a small number ofsubjects; however, further homogeneity tests did not support any
evidence for differences between the strata (Supplemental Table S8).
Similarly, rs3804451GA/AA carriers also had a shorter OS in most of the
subgroups (Supplemental Table S8). There was a difference in HRs
between subgroups with or without the TKI treatment for MAPK14
rs3804451 (P = .001) (Table 2) by the homogeneity test, as shown in
Kaplan-Meier survival curves (Figure 3, A and B), which were consistent
with the results from the Cox regression analysis of interaction (P = .014)
between rs3804451 and TKI treatment with adjustment for age at
treatment, sex, smoking status, TNM stage, histological type, histologic
grade, ECOG performance status, chemotherapy regimens, grade 3/4
chemotherapy toxicity, and palliative radiotherapy.
Our previous study demonstrated that carriers of the MAPK14
rs3804451A variant allele had a significantly higher risk for grade 3/4
overall chemotherapy toxicity [22]; nevertheless, the effects of
rs3804451GA/AA genotypes on PFS (Figure 3, C and D) and OS
(Figure 3, E and F) between different toxicity subgroups showed no
difference in the present study (P = .676 and .090, respectively)
(Supplemental Table S8), suggesting that there was a direct effect of
the A allele on PFS and OS, which was not mediated by the toxicity.
Correlation between MAPK14 Genotypes and mRNA Expression
Levels
Finally, we used experimental data of MAPK14 mRNA expression
levels and SNP genotypes of the target tumor tissues from 170 unrelated
Chinese NSCLC patients to evaluate the effect of the rs3804451A allele
on the mRNA expression. There were 108 GG carriers, 55 GA carriers,
and 7 AA carriers (Figure 4A). MAPK14 mRNA expression levels of
tumor tissues with rs3804451GA/AA genotypes were higher than those
with the GG genotype (P = .048) (Figure 4B).
Discussion
In the present study, we investigated, in a two-step study design, the
associations of potentially functional 11 SNPs of 9 genes in the JNK
and P38α pathways with PBC response and survival outcomes in
Figure 1. Kaplan-Meier curves of PFS and OS by the MAPK14 rs3804451 genotype in all patients combined. PFS in an additive genetic
model (A) and a dominant genetic model (B) and OS in an additive genetic model (C) and a dominant genetic model (D).
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population. The MAPK14 rs3804451A allele was found to be
significantly associated with PBC resistance and a shorter PFS and OS
of the patients. We also observed that MAPK14 mRNA expression
levels of tumor tissues with rs3804451 GA/AA genotypes were higher
than those with the GG genotype, which provides additional
biological support for the observed associations with survival in
response to PBC in the patients.
PBC is still the first-line treatment for most patients with advanced
NSCLC, although target therapy and immunotherapy are recently
developed and used to treat NSCLC patients. However,
platinum-based double-agent chemotherapy has a low response rate
but a high toxicity occurrence rate. Its main effect is thought to
enhance cell apoptosis and autophagy [6,30]. Many studies have
focused on the roles of JNK and P38α pathways in the response of
tumors to chemotherapeutic agents, such as platinum compounds. It
has been shown that cisplatin sensitivity depends on a long-term
cisplatin-induced activation of JNK and P38α pathways [31,32]. If
the P38a pathway of tumor cells is constitutively activated under
normal conditions, tumor cells will attenuate to further activate P38
MAPK, which is essential to induce cell apoptosis in response to
cisplatin [33]. Indeed, it has been shown that cancer cell lines with
high baseline levels of the P38 MAPK activity tend to be more
resistant to cisplatin [34].
The rs3804451 SNP is located on the 3′ untranslated region of
MAPK14 (P38a) and likely to be functional as predicted by SNPInfo
[22]. Indeed, in the present study, we showed that the high expression
levels of P38a in tumor tissues were associated with the A allele. In
fact, studies have shown that baseline hyperactivation of the P38a
pathway exists in lung cancer samples [35] and is correlated withchemoresistance [33]. The fact that patients with the rs3804451A
variant allele have a significantly increased P38a mRNA expression
levels provides a biological plausibility that rs3804451A variant
carriers may tend to be more resistant to PBC than patients without
the A allele. However, this finding needs to be tested through
additional in vivo and in vitro functional studies.
In the stratification analysis, the effect of the rs3804451A allele was
still statistically significant in most of the subgroups. Because our
previous study suggested that carriers of MAPK14 rs3804451GA/AA
genotypes had a significantly higher risk for grade 3/4 overall
chemotherapy toxicity [22], it is likely that the rs3804451A allele may
reduce survival time by increasing chemotherapy toxicity. However,
further homogeneity tests between subgroups with or without grade
3/4 overall chemotherapy toxicity did not appear to support any
difference between these two subgroups. This may suggest that the
rs3804451 SNP is associated with toxicity of normal tissue and
sensitivity of tumor tissue in response to PBC. Interestingly, we found
that there was a significant difference in HRs between subgroups with
or without the TKI treatment, likely because the rs3804451 may only
modulate the chemotherapy response of tumor tissues; as the TKI
treatment significantly prolongs survival time of patients with
sensitive EGFR mutations, the effect of the rs3804451A allele in
these patients may be greatly masked by the TKI treatment. This may
also explain why there was no significant increase in the efficacy of the
OS prediction model when adding the rs3804451 SNP to the same
model including other selected variables. Nevertheless, these results
need to be validated in future studies with large sample sizes.
In the context of cancer, mechanisms of the resistance to platinum
compounds are complex [7,36] because tumors may have
disease-specific mutations and carry germline variants that affect
Figure 2. Time-dependent ROC curves for the prediction of 1-year (A), 3-year (B), and 5-year OS rate (C) based on only selected variables
(sex, smoking status, TNM stages, palliative radiotherapy, and TKI treatment) and the combined rs3804451 genotypes along with clinical
variables; incident/dynamic AUC plots for the present study data (D) based on only selected variables and combined variables.
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tively affect drug response [37]. Therefore, it would lead to bias if we





Variables GG GA/AA Adjusted HR (95% CI) P Phom
TKI treatment
No 136/323 72/130 1.84 (1.36-2.48) b.0001
Yes 94/189 30/68 0.86 (0.56-1.33) .505 .001
Abbreviation: hom, heterogeneity test. The results were in bold if P b .05.
Adjusted by age at treatment, sex, smoking status, TNM stage, histological type, histologic grade, ECOG
performance status, chemotherapy regimens, grade 3/4 chemotherapy toxicity, and palliative radiotherapy.prediction with either genetic or clinical factors, let alone a single SNP
from one gene. However, a tentative predictive model with an
increased prediction accuracy by adding both genetic and clinical
factors with known significant associations with chemotherapy
sensitivity has been established [38]. There is room for additional
improvement by identifying other important genomic information
(including somatic mutations, germline variants, epigenetic factors,
etc.) of tumor tissues in response to PBC, which will lead to a better
predictive model to distinguish patients who tend to benefit from
PBC from those who do not.
However, the present study has some limitations. First, all patients
were treated at the same hospital and may have selection bias and
information bias. Studies from other patient populations are needed
to validate our findings. Also, because of the retrospective nature of
the original study design, EGFR mutation information of the patients
Figure 3. Kaplan-Meier curves of OS by the dichotomized rs3804451GA/AA genotypes for patients without (A) and with (B) TKI;
Kaplan-Meier curves of PFS by the dichotomized rs3804451GA/AA genotypes for patients without (C) and with (D) grade 3/4
chemotherapy toxicity; Kaplan-Meier curves of OS by the dichotomized rs3804451GA/AA genotypes for patients without (E) and with (F)
grade 3/4 chemotherapy toxicity.
Figure 4. mRNA expression levels by MAPK14 rs3804451 genotypes in tumor tissues of 170 patients. (A) An additive genetic model for
rs3804451 (108, 55, and 7 for GG, GA, and AA, respectively; P = .171); (B) a dominant genetic model for rs3804451 (108 and 62 for GG
and GA/AA, respectively; P = .048).
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538 P38α rs3804451 variant predicts NSCLC survival Jia et al. Translational Oncology Vol. 9, No. 6, 2016only treated by chemotherapy was largely missing, which may
influence patients' survival. Finally, this study was only performed in
a Chinese patient population, and the results may not be generalizable
to the general populations or other ethnic groups. Therefore,
well-designed, large studies in other ethnic populations with
advanced-NSCLC patients are necessary to validate our findings.
Conclusions
The present study provides evidence that the MAPK14 rs3804451
GNA SNP may modulate PBC-related survival outcomes in Chinese
patients with advanced NSCLC. Such information about genetic
factors could be used to guide the selection of proper treatment in the
future, if validated in large-scale, perspective studies.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2016.09.006.
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